(VIANEWS) – ESSILORLUXOTTICA (EL.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| ESSILORLUXOTTICA (EL.PA) | €170.64 | 1.75% | 6.16% |
| MEDISTIM (MEDI.OL) | kr279.00 | 1.61% | 31.89% |
| VETOQUINOL (VETO.PA) | €89.20 | 0.91% | 10.37% |
| SARTORIUS STED BIO (DIM.PA) | €224.70 | 0.62% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ESSILORLUXOTTICA (EL.PA)
1.75% Forward Dividend Yield and 6.16% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €4.83.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 35.33. Meaning, the purchaser of the share is investing €35.33 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
More news about ESSILORLUXOTTICA.
2. MEDISTIM (MEDI.OL)
1.61% Forward Dividend Yield and 31.89% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.14.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 45.44. Meaning, the purchaser of the share is investing kr45.44 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
More news about MEDISTIM.
3. VETOQUINOL (VETO.PA)
0.91% Forward Dividend Yield and 10.37% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.08.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 21.86. Meaning, the purchaser of the share is investing €21.86 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
Volatility
VETOQUINOL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.15%, a negative 0.04%, and a positive 1.16%.
VETOQUINOL’s highest amplitude of average volatility was 1.15% (last week), 0.86% (last month), and 1.16% (last quarter).
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 2, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.91%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 539.78M for the twelve trailing months.
More news about VETOQUINOL.
4. SARTORIUS STED BIO (DIM.PA)
0.62% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €7.78.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 28.88. Meaning, the purchaser of the share is investing €28.88 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
More news about SARTORIUS STED BIO.
